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Abstract
Aims/hypothesis We investigated associations of allelic
variations in the WFS1 gene with insulin secretion and risk
of type 2 diabetes in a general population prospective study.
Methods We studied 5,110 unrelated French men and
women who participated in the prospective Data from
Epidemiological Study on the Insulin Resistance Syndrome
(DESIR) study. Additional cross-sectional analyses were
performed on 4,472 French individuals with type 2 diabetes
and 3,065 controls. Three single nucleotide polymorphisms
(SNPs) were genotyped: rs10010131, rs1801213/rs7672995
and rs734312.
Results We observed statistically significant associations
between the major alleles of the three variants and prevalent
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type 2 diabetes in the DESIR cohort at baseline. Cox
analyses showed an association between the G-allele of
rs10010131 and incident type 2 diabetes (HR 1.34, 95% CI
1.08–1.70, p=0.007). Similar results were observed for the
G-allele of rs1801213 and the A-allele of rs734312. The
GGA haplotype was associated with an increased risk of
diabetes as compared with the ACG haplotype (HR 1.26,
95% CI 1.04–1.42, p=0.02). We also observed statistically
significant associations of the three SNPs with plasma
glucose, HbA1c levels and insulin secretion at baseline and
throughout the study in individuals with type 2 diabetes or
at risk of developing diabetes. However, no association was
observed in those who remained normoglycaemic at the end
of the follow-up. Associations between the three variants
and type 2 diabetes were replicated in cross-sectional
studies of type 2 diabetic patients in comparison with a
non-diabetic control group.
Conclusions/interpretation The most frequent haplotype at
the haplotype block containing the WFS1 gene modulated
insulin secretion and was associated with an increased risk
of type 2 diabetes.
Keywords Endoplasmic reticulum stress . Genetic
epidemiology . Population studies .Wolframin
Abbreviations
ATF6α Activating transcription factor 6α
DESIR Data from Epidemiological Study on the
Insulin Resistance Syndrome
DIABHYCAR The Diabetes, Hypertension,
Cardiovascular Events, and Ramipril study
ER Endoplasmic reticulum
FPG Fasting plasma glucose
GLP-1 Glucagon-like peptide 1
IFG Impaired fasting glucose
HOMA%B HOMA index of beta cell function
HOMA%S HOMA index of insulin sensitivity
NCH Necker and Cochin Hospitals
NFG Normal fasting glucose
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WFS1 Wolframin
Introduction
Wolframin (WFS1) is a transmembrane protein of the
endoplasmic reticulum (ER), found ubiquitously but with
higher levels in pancreatic beta cells and specific neurons of
the central nervous system [1]. WFS1 is a component of the
unfolded protein response following ER stress [2]. It
controls a negative regulatory feedback loop of the ER
stress signalling network, acting as an ER stress signalling
suppressor [3]. ER stress signalling is tightly regulated in
pancreatic beta cells to produce appropriate amounts of
insulin in response to the frequent fluctuations of blood
glucose levels [4, 5]. WFS1 is upregulated during insulin
secretion and plays an important role in maintaining ER
homeostasis and cell integrity in pancreatic beta cells [2].
Inactivation of the wolframin gene (Wfs1) in beta cells of
rodents causes ER stress and beta cell death by accelerated
apoptosis [2, 3, 6].
Mutations in WFS1 are responsible for Wolfram syn-
drome [7, 8], a rare recessive disorder characterised by
diabetes mellitus, optic atrophy and other neurological and
endocrine abnormalities [9]. An increased prevalence of
diabetes mellitus was reported in first-degree relatives of
patients with Wolfram syndrome [10], suggesting a possible
effect of WFS1 mutation heterozygosis. More recently,
common variants of WFS1 were shown to be associated
with type 2 diabetes in populations of European descent
[11–13]. Associations of these variants with insulin
secretion in response to oral or intravenous glucose was
observed in some [14, 15], but not all studies [16–18]. In
the present study, we investigated associations of allelic
variations in the WFS1 gene with insulin secretion, insulin
sensitivity and the risk of hyperglycaemia (impaired fasting
glucose [IFG]) and of type 2 diabetes in a 9 year
population-based prospective cohort. We tested the hypoth-
esis that discrepancies in the associations between WFS1
variants and insulin secretion in previous reports could be
related to differences in glycaemic and/or diabetes risk
status of studied populations. For the purpose of replication,
associations between WFS1 variants and diabetes were also
investigated in three independent type 2 diabetes cross-
sectional cohorts.
Methods
Participants in prospective study: the DESIR cohort The
Data from Epidemiological Study on the Insulin Resistance
syndrome (DESIR) study was a 9 year prospective study
conducted in 5,212 men and women from the French
general population [19, 20]. Participants were recruited in
ten healthcare centres in the western central part of France
on the occasion of periodic health check-ups offered by
Social Security. The study protocol included clinical and
biological evaluations at inclusion and at visits after 3, 6
and 9 years of follow-up. Glycaemic status was classified in
three groups, defined on the basis of fasting plasma glucose
(FPG) and hypoglycaemic medication. Normal fasting
glucose (NFG) was defined as FPG <6.1 mmol/l and IFG
as FPG between 6.1 and 6.99 mmol/l, in the absence of
treatment with a hypoglycaemic agent for both classes.
Type 2 diabetes was defined as FPG ≥7.0 mmol/l or as
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FPG <7.0 mmol/l in the presence of treatment with a
diabetes drug and a previous diagnosis of diabetes. The
research protocol was approved by the ethics committee of
Bicêtre Hospital and all participants signed an informed
consent form. At baseline, 4,634 individuals (88.9%) had
NFG, 342 (6.6%) IFG and 134 (2.6%) diabetes. The
glycaemic status of 102 participants (1.9%) could not be
ascertained at baseline and they were excluded from the
analyses. NFG individuals lost during follow-up and whose
final glycaemic status could not be determined (n=1,003)
were excluded from the analyses of incidence. For the
purpose of this investigation, we have considered the
incidence of type 2 diabetes and the incidence of hyper-
glycaemic events (NFG to IFG, NFG to diabetes or IFG to
diabetes change) during follow-up. The incidence of type 2
diabetes was 5.1% (203 cases out of 3,973 NFG or IFG
cases at baseline), while the incidence of hyperglycaemic
events was 16.7% (663 cases out of 3,973 NFG or IFG
cases at baseline).
Participants in cross-sectional studies: DIABHYCAR, DIA-
BHYCAR Gene and NCH cohorts The Diabetes, Hyperten-
sion, Cardiovascular Events, and Ramipril (DIABHYCAR)
study was a 6 year double-blind multicentre multinational
clinical trial conducted in 4,912 men and women who had
type 2 diabetes, were aged 50 years or older at baseline and
were selected on the basis of persistent micro- or macro-
albuminuria without renal failure. The trial tested in a
parallel design and vs placebo whether a low dose of
ramipril that was able to reduce urinary albumin concen-
tration would also reduce cardiovascular and/or renal events
such as myocardial infarction, stroke, acute heart failure,
end-stage renal failure and cardiovascular death. The study
design, methods and results of the trial (which were
negative regarding the drug effect) have been published
previously [21, 22]. DNA banking was undertaken for the
3,137 participants recruited in France. The DIABHYCAR
Gene cohort was recruited concomitantly to DIABHYCAR.
It included 607 men and women with type 2 diabetes, aged
50 years or older at baseline and not presenting with micro-
or macroalbuminuria. The study protocols of the two
cohorts were approved by the Angers University Hospital
Ethics Committee. The Necker and Cochin Hospitals
(NCH) cohort included type 2 diabetic men and women
consecutively recruited at the diabetes departments of NCH
in Paris [23]. The present investigation included 728
individuals of European descent. Clinical and biological
data were obtained from medical records. The study
protocol was approved by the Ethics Committee of Hôpital
Necker. For the purpose of these cross-sectional studies, the
three cohorts of type 2 diabetic patients were compared
with a control group of 3,065 participants from the DESIR
cohort who had remained normoglycaemic at the 9-year
follow-up (DESIR controls). This group from the French
general population has been extensively used as a control
group in genetic studies [24, 25].
DNA studies The WFS1 gene spans ∼33.4 kbp on chromo-
some 4p16 and is contained in a single haplotype block.
Three single nucleotide polymorphisms (SNPs) were
genotyped using assay by design kits from Applied
Biosystems (Life Technologies, Carlsbad, CA, USA):
rs10010131 (G>A, intron 4), rs1801213/rs7672995 (G>C,
R228R, exon 6) and rs734312 (A>G, H611R, exon 8). The
SNPs were chosen in HapMap on the basis of capturing
information on ∼80% of the allelic variation of SNPs with
minor allele frequency ≥5% at r2>0.8 in the haplotype
block containing WFS1.
Computations and statistical analyses HOMA index of
beta cell function (HOMA%B) and of insulin sensitivity
(HOMA%S) [26], based on fasting levels of glucose and
insulin, were computed using the Microsoft Excel spread-
sheet implementation of the HOMA Calculator (v2.2)
available at www.dtu.ox.ac.uk/Homacalculator/download.
php (accessed 1 March 2006). Before genotype-related
statistical analyses were performed, genotypes were verified
to be in Hardy–Weinberg equilibrium in all groups of
participants. Genotype associations with diabetes or hyper-
glycaemia were assessed by regression models. Cox
proportional hazards survival regression analyses were used
to examine the effect of explanatory variables on time-
related survival (disease-free) rates in prospective analyses.
Kaplan–Meier curves were used to plot survival (disease-
free) rates over time according to genotype. Logistic
regression analyses were used for cross-sectional analyses.
Hazard ratios or odds ratios, respectively, with 95% CIs,
were computed in these analyses for the risk allele. Adjust-
ments for clinical and biological variables were carried out
by including these variables as covariates in the regression
model. The study had power >0.99 to detect associations of
the SNPs with the incidence of diabetes in the DESIR study
(for HR ≥1.2 and α=0.05) and with the prevalence of
diabetes in the cross-sectional study (for OR ≥1.3 and α=
0.05). It had power >0.80 (for α=0.05) to detect differences
in quantitative traits >10% between groups.
Comparisons of anthropometric, clinical and biological
phenotypes between groups were assessed by ANOVA,
analyses of covariance, contingency table χ2 test and
Fisher’s exact test. For the comparisons of FPG, HbA1c,
insulin, HOMA%B and HOMA%S between genotypes,
interaction between the glycaemic status at follow-up (NFG
or IFG/diabetes) and genotype was assessed by including in
the regression model a ‘crossed’ compound covariable
(glycaemic status/genotype). Stratification by glycaemic
status of genotype-related effects on phenotypic traits was
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then performed by nesting the genotype variable within the
glycaemic status variable in the regression analysis. This
results in the computation of separate statistical effects for
NFG and IFG/diabetes subgroups of individuals, adjusted
for multiple comparisons due to the stratification by
glycaemic status. For all analyses, data were log-
transformed for the analyses when the normality of the
distribution was rejected by the Shapiro–Wilk W test.
Results are expressed as means±SEM. p<0.05 was
considered significant. Giving the strong linkage disequi-
librium between the SNPs (see below), no p value
correction for multiple SNP testing was performed, as it
was considered that they were not independent analyses.
Statistics were performed with JMP software (SAS Insti-
tute, Cary, NC, USA). Power calculations were performed
with Quanto v1.2.4 (http://hydra.usc.edu/gxe; accessed 10
June 2009) and Logistic_Cox_Power (http://hedwig.mgh.
harvard.edu/biostatistics/node/19; accessed 10 June 2009).
Determination of linkage disequilibrium between SNPs and
between haplotype frequencies, and computation of hazard
and odd ratios associated with haplotypes were performed
with THESIAS software v3.1 (http://ecgene.net/genecanvas/
uploads/THESIAS3.1/Documentation3.1.htm; accessed 15
January 2010) [27].
Results
Prospective study: DESIR cohort Prevalence studies were
conducted in 5,110 participants from the DESIR cohort
(Table 1). The combined prevalence at baseline of IFG/
diabetes according to genotype was: 10.3% (GG), 9.3%
(GA) and 7.5% (AA) for rs10010131; 9.8% (GG), 9.3%
(GC) and 7.5% (CC) for rs1801213; and 10.4% (AA), 9.4%
(AG) and 7.8% (GG) for rs734312. Logistic regression
analyses showed associations of the major allele of the
three variants with diabetes and with the combined
prevalence of IFG/diabetes at baseline (Table 2). When
we considered the prevalence of IFG only, associations
were also observed for rs10010131 and rs734312, while
only a trend towards an association was observed for
rs1801213 (Table 2).
The main baseline characteristics of incident cases of
type 2 diabetes or hyperglycaemic events are shown in
Electronic supplementary material (ESM) Table 1. The
incidence of type 2 diabetes according to genotype was:
5.5% (GG), 5.4% (GA) and 3.6% (AA) for rs10010131;
5.2% (GG), 5.4% (GC) and 3.3% (CC) for rs1801213; and
5.5% (AA), 5.6% (AG) and 4.0% (GG) for rs734312. This
suggests a dominant effect of the major allele for all SNPs
(Fig. 1). Cox proportional hazards survival regression
analyses showed a statistically significant association
between the G-allele of rs10010131 and the incidence of
type 2 diabetes (HR 1.34, 95% CI 1.08–1.70, p=0.007 for a
dominant GX vs AA model; Table 3). Similar results were
observed for the G-allele of rs1801213 (HR 1.44, 95% CI
1.10–1.99, p=0.007) and for the A-allele of rs734312 (HR
1.22, 95% CI 1.02–1.48, p=0.03). Haplotype frequencies
were determined for incident cases of diabetes and for
participants who did not develop diabetes during the
follow-up (NFG/IFG censored individuals) and Cox sur-
vival (disease-free) analyses were performed for the
haplotypes. There was a strong linkage disequilibrium
between the three SNPs (0.74≤D'≤0.93), with haplotypes
composed of the major (GGA) or minor (ACG) alleles of
the variants representing ∼77% of all haplotypes. GGA
frequency was 51.0% in incident cases of type 2 diabetes
and 47.6% in NFG/IFG censored individuals, while ACG
frequencies were 26.6% and 29.2%, respectively. The GGA
haplotype was significantly associated with an increased
risk of diabetes compared with the ACG haplotype (HR
Characteristic Glycaemic status
NFG IFG Type 2 diabetes p value
n 4,634 342 134
Age (years) 46.8±0.1 51.9±0.5 55.0±0.7 <0.0001
Sex <0.0001
Men (%) 47 73 71
Women (%) 53 27 29
BMI (kg/m2) 24.5±0.1 26.9±0.2 28.9±0.3 <0.0001
FPG (mmol/l) 5.20±0.01 6.40±0.03 8.40±0.06 <0.0001
HbA1c (%) 5.40±0.01 5.83±0.03 6.87±0.04 <0.0001
Fasting insulin (pmol/l) 45±1 65±2 87±2 <0.0001
HOMA%B (%) 77±1 65±1 54±2 <0.0001
HOMA%S (%) 146±1 100±3 85±5 <0.0001
Table 1 Clinical and biological
characteristics at baseline
according to glycaemic status,
the DESIR cohort
Except where otherwise indi-
cated, data are expressed as
mean±SEM
Comparisons are by ANOVA
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1.26, 95% CI 1.04–1.42, p=0.02, comparison adjusted for
sex, age and BMI).
The incidence of hyperglycaemic events according to
genotype was: 17.1% (GG), 16.5% (GA) and 16.7% (AA)
for rs10010131; 17.4% (GG), 16.5% (GC) and 15.3% (CC)
for rs1801213; and 16.2% (AA), 17.7% (AG) and 15.9%
(GG) for rs734312. Cox proportional hazards survival
regression analyses showed a trend towards an association
between the G-allele of rs1801213 and the incidence of
hyperglycaemic events (HR 1.11, 95% CI 0.99–1.25, p=
0.08 for a co-dominant additive model) (ESM Table 2),
while no association was observed for the other variants.
We assessed the impact of the SNPs on intermediate
phenotypes such as FPG, HbA1c, fasting insulin, and
HOMA%B (insulin secretion) and HOMA%S (insulin
sensitivity) indices. Analyses were performed with baseline
values and with all available values collected throughout
the study (baseline plus values at 3, 6 and 9 year visits).
Results at baseline for rs10010131 genotypes are shown in
Table 4. These phenotypic analyses revealed a strong
interaction between genotype and glycaemic status at the
end of the study (NFG or IFG/diabetes). Genotype-related
effects on intermediate traits were observed in the subset of
the population presenting with IFG or diabetes at the end of
the study, but not in individuals with NFG. In the former
subset of the population, significantly higher FPG and
HbA1c levels and lower HOMA%B levels were observed in
carriers of the GG risk genotype than in AA carriers.
HOMA%S was not significantly different between groups.
The exclusion of participants receiving sulfonylurea (n=15),
metformin (n=15) or both (n=12) had no significant effect
on the computations. Comparable results were observed
when we considered the values of these variables collected
throughout the study (ESM Table 3). Similar results were
Table 2 Genotype frequency according to glycaemic status at baseline, the DESIR cohort
Genotype by SNP Glycaemic status OR (95% CI) for comparison of genotype frequency by glycaemic status
NFGa IFGb DMc IFG vs NFG p value DM vs NFG p value IFG/DM vs NFG p value
rs10010131
GG 0.369 0.385 0.466 1.39 (1.00–1.94) 0.05 1.98 (1.15–3.45) 0.01 1.50 (1.11–2.02) 0.008
GA 0.482 0.506 0.397
AA 0.149 0.109 0.137
rs1801213
GG 0.472 0.485 0.530 1.38 (0.97–1.98) 0.07 1.47 (1.02–2.11) 0.04 1.43 (1.05–1.97) 0.02
GC 0.433 0.452 0.366
CC 0.095 0.063 0.104
rs734312
AA 0.292 0.317 0.354 1.47 (1.06–2.04) 0.02 1.62 (1.0–2.72) 0.05 1.51 (1.13–2.01) 0.005
AG 0.494 0.515 0.446
GG 0.214 0.168 0.200
Values are ORs for the major alleles in a co-dominant model, adjusted for sex, and for age and BMI at baseline
a n=4,634, b n=342, c n=134
DM, type 2 diabetes mellitus
Fig. 1 Kaplan–Meier survival (disease-free) curves for the DESIR
cohort during follow-up according to genotype. a rs10010131, AA
(dashed line), GA (dotted line), GG (solid line); (b) rs1801213, CC
(dashed line), GC (dotted line), GG (solid line); and (c) rs734312, GG
(dashed line), AG (dotted line), AA (solid line)
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also observed for the other two SNPs, both at baseline and
throughout the study (data not shown).
Cross-sectional study: DIABHYCAR, DIABHYCAR Gene
and NCH cohorts Clinical characteristics of participants
from the type 2 diabetes cohorts and from the control
cohort are shown in ESM Table 4. A logistic regression
analysis was performed for each SNP with the cohort
membership as the dependent variable, genotype as
independent covariable, and sex, age and BMI as adjust-
ment covariables. Odds ratio associated with genotype was
computed for each type 2 diabetes cohort against the
control cohort (ESM Table 5). Statistically significant
associations of the major allele of the three variants with
diabetes was confirmed in all type 2 diabetes cohorts
individually, as well as with pooled data of the three
cohorts. Linkage disequilibrium between the variants was
computed and haplotype frequencies were determined for
patients and for controls. A logistic regression analysis was
performed with glycaemic status as the dependent variable,
the haplotypes as independent covariable, and sex, age and
BMI as adjustment covariables (ESM Table 6). The GGA
haplotype (major allele of the three variants) was signifi-
cantly associated with diabetes compared with the ACG
haplotype (minor alleles of the variants).
Discussion
We observed statistically significant associations of the
major alleles of rs10010131, rs1801213 and rs734312 in
the WFS1 locus with an increased risk of type 2 diabetes in
individuals with NFG or IFG in a 9 year prospective study
in a French cohort issued from the general population. Only
a trend towards an association with one of the variants
(rs1801213) was observed when we considered the inci-
dence of all hyperglycaemic events (NFG to IFG, NFG to
Genotype by SNP Incidence of diabetes HR (95% CI) for incidence p value
Noa Yesb
rs10010131
GG 0.372 0.395 1.34 (1.08–1.70) 0.007
GA 0.476 0.500
AA 0.152 0.105
rs1801213
GG 0.474 0.482 1.44 (1.10–1.99) 0.007
GC 0.430 0.457
CC 0.096 0.061
rs734312
AA 0.295 0.309 1.22 (1.02–1.48) 0.03
AG 0.489 0.527
GG 0.216 0.164
Table 3 Genotype frequency
according to incidence of
diabetes during follow-up, the
DESIR cohort
Hazard ratios (HR) for the major
alleles in a dominant model (MX
vs mm) determined by Cox
proportional hazards survival
regression analyses adjusted for
sex, and for age and BMI at
baseline. Time to event was
defined as the number of years
of follow-up until the diagnosis
of type 2 diabetes or the dura-
tion of follow-up for right-
censored participants without
diabetes at the end of follow-up
a n=3770, b n=203
Table 4 Intermediate phenotypes at baseline according to rs10010131 genotype and glycaemic status at follow-up, the DESIR cohort
Glycaemic status NFG p value IFG/type 2 diabetes p value Interaction
p value a
Genotype GG GA AA GG GA AA
Participants (n) 1,111 1,421 459 400 482 141
FPG (mmol/l) 5.18±0.02 5.17±0.02 5.20±0.04 0.80 6.17±0.04 6.09±0.04 5.87±0.06 0.0005 0.002
HbA1c (%) 5.40±0.01 5.39±0.01 5.41±0.02 0.64 5.82±0.03 5.71±0.02 5.61±0.04 <0.0001 <0.0001
Fasting insulin (pmol/l) 45±1 44±1 45±1 0.47 53±1 57±1 59±2 0.31 0.60
HOMA%B (%) 77±1 77±1 77±1 0.92 65±1 67±1 71±2 0.0002 0.0009
HOMA%S (%) 146±2 147±1 144±3 0.86 125±3 124±3 123±5 0.23 0.34
Unless otherwise stated, data are expressed as mean±SEM
Comparisons are analysis of covariance, adjusted for sex, age and BMI, and computed with log-transformed data
a Indicates the statistical significance observed in the regression model for a crossed compound covariable ‘glycaemic status–genotype’
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diabetes or IFG to diabetes change) during follow-up. The
variants were also associated with the prevalence of IFG
and/or diabetes at baseline. Together, these results suggest
that allelic variations of WFS1 increase the risk of diabetes,
but have a lesser impact on the risk of IFG in the DESIR
cohort. Associations with diabetes were confirmed in cross-
sectional studies of three cohorts of type 2 diabetic patients
compared with normoglycaemic controls. The most fre-
quent haplotype at the haplotype block containing the
WFS1 gene was associated with an increased risk of
diabetes in the prospective study and with the prevalence
of diabetes in cross-sectional studies.
Our results are in agreement with data from the
literature. Sandhu and co-workers identified associations
of the major alleles of rs10010131, rs6446482, rs752854
and rs734312 SNPs with WFS1 and diabetes risk in 9,533
cases and 11,389 controls from UK and Ashkenazi
populations [11]. Lyssenko and co-workers observed an
association between the major allele of rs10010131 and an
increased risk of diabetes in two prospective cohorts with a
median follow-up of 23.5 years and including 16,061
Swedish and 2,770 Finnish participants [13]. An associa-
tion between rs752854 and type 2 diabetes was also
observed in a Swedish cross-sectional study of 1,296 cases
and 1,412 controls, with the minor allele conferring
protection against diabetes [12]. Other studies have yielded
less conclusive results. Florez and co-workers examined the
effects of the rs10010131, rs752854 and rs734312 variants
on diabetes incidence and response to interventions in the
Diabetes Prevention Program, in which a lifestyle interven-
tion or metformin treatment was compared with placebo
[28]. They found no statistically significant interactions
between genotypes and Diabetes Prevention Program
intervention for any of the SNPs. None showed a
statistically significant effect on diabetes incidence in the
entire cohort, although in the lifestyle arm homozygosis for
the minor alleles was consistent with protection from
diabetes. Only a trend towards association with diabetes
was observed for the rs10010131 variant in a Chinese
cross-sectional study of 1,849 type 2 diabetic patients and
1,785 controls [16]. Although it is clear that WFS1
mutations cause diabetes [7, 8], the genetic basis of the
association of these common WFS1 variants with type 2
diabetes is still unclear. A recent fine-mapping study in UK,
Swedish and Ashkenazi populations identified six novel,
highly correlated SNPs showing strong and comparable
associations with type 2 diabetes risk [29]. None had
obvious functional properties that could predict deleterious
effects on protein function. Given the strong linkage
disequilibrium in the WFS1 region, the authors suggested
that further refinement of these associations for identifica-
tion of the variants responsible for increased diabetes risk
would require studies in ethnically diverse populations and/
or studies with much larger sample sizes (10,000 to
100,000 individuals) [29].
We also observed statistically significant associations of
the risk alleles of the three SNPs with higher FPG and
HbA1c levels, and lower HOMA%B levels, both at baseline
and throughout the study in participants who developed
hyperglycaemia or type 2 diabetes. Interestingly, no allelic
association with these intermediate phenotypes was ob-
served in individuals who remained normoglycaemic at the
end of the follow-up. The design of our study had some
intrinsic limitations. Glucose tolerance status of participants
was based on FPG only and not on an OGTT. Second,
insulin secretion and insulin sensitivity were assessed by
HOMA indices, which provide only an estimation of these
variables. Nonetheless, we do not believe that these
limitations have substantially biased our results, as they
are in agreement with other observations. Sparso and co-
workers observed a similar interaction between the glycae-
mic status and the genotype effect of rs734312 on insulin
secretion in the Inter99 cohort, which involved 4,568
glucose-tolerant individuals and 1,471 individuals with
treatment-naive abnormal glucose regulation (IFG, im-
paired glucose tolerance or screen-detected diabetes) [14].
The risk allele was associated with a decrease in insulino-
genic index and decreased 30 min serum insulin levels after
an oral glucose load in individuals with abnormal glucose
regulation, but not in participants with normal glucose
tolerance. It seems that this interaction between glycaemic
status and genotype might explain the heterogeneous results
reported by previous studies of associations between WFS1
variants and insulin secretion. Schafer and co-workers
studied 1,578 non-diabetic German individuals at increased
risk of type 2 diabetes, i.e. persons with a history of
gestational diabetes, IFG, impaired glucose tolerance or
family history of type 2 diabetes in first-degree relatives
[15]. They found that the rs10010131 risk allele was
associated with reduced insulin secretion during an OGTT.
Interestingly, insulin secretion in response to an IVGTT or a
hyperglycaemic clamp was not different between geno-
types. However, when the hyperglycaemic clamp was
combined with a glucagon-like peptide 1 (GLP-1) infusion,
first- and second-phase insulin secretion were significantly
decreased in carriers of the risk allele. A study from the
Netherlands with similar size and power, but performed in
participants with normal glucose tolerance, observed no
significant genotype effect on insulin secretion in response
to GLP-1 and glucose infusion during a hyperglycaemic
clamp [17]. Other studies in large cohorts of non-diabetic
Finnish [18] or Chinese [16] participants observed no
association between rs10010131 and insulin secretion
during an OGTT.
WFS1 protects cells from the damaging effects of
hyperactivation of ER stress signalling [3]. ER stress is
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caused by physiological and pathological stimuli that lead
to accumulation of a large load of unfolded and misfolded
proteins in the ER. For instance, physiological ER stress
occurs in pancreatic beta cells during postprandial stimula-
tion of insulin synthesis [30]. Activation of ER stress
signalling is tightly regulated because hyperactivation or
chronic activation of this signalling pathway can cause cell
death by inducing apoptosis [31]. Recent results have
shown that WFS1 has an important function in the tight
regulation of ER stress through its interaction with
activating transcription factor 6α (ATF6α), a key transcrip-
tion factor implicated in ER stress signalling [3]. WFS1
recruits ATF6α to the proteasome, where in the absence of
ER stress it undergoes degradation. In situations of ER
stress, ATF6α is released from WFS1 in the ER membrane
and translocates to the nucleus, where it upregulates stress
signalling targets. As WFS1 is induced by ER stress, it
causes eventual degradation of ATF6α when ER homeo-
stasis is established.
A possible reason why WFS1 variants only associate
with insulin secretion in individuals with abnormal glucose
regulation is that these polymorphisms have only a minor
impact on WFS1 function in physiological situations. Thus,
their effect on insulin secretion can be best appreciated in
situations of chronic activation of ER stress signalling, such
as in participants with decreased insulin sensitivity and
chronic stimulation of insulin synthesis. Moreover, partic-
ipants with abnormal glucose regulation may have other
stressors of beta cell function, including unfavourable
alleles in other pancreatic beta cell genes, as well as
glucotoxicity, lipotoxicity or defects in the potentiation of
insulin secretion by incretins (GLP-1, glucose-dependent
insulinotropic polypeptide) [32], which could interact with
susceptibility variants of WFS1 and aggravate ER stress-
mediated apoptosis. WFS1 risk alleles have been shown to
be associated with reduced insulin response to oral, but not
to intravenous glucose [14, 15], and with reduced response
to GLP-1 stimulation during hyperglycaemic clamps [15].
This suggests an incretin-related defect. GLP-1 not only
enhances insulin secretion in response to glucose, but also
directly modulates the ER stress response, preventing beta
cell apoptosis and promoting beta cell adaptation and
survival [32, 33]. At the present time, the mechanisms of
the putative interaction of GLP-1 signalling and WFS1 on
ER function are still unclear.
In conclusion, allelic variations in the WFS1 gene
modulated insulin secretion in normoglycaemic French
individuals at risk of developing type 2 diabetes and also
increased the risk of type 2 diabetes in a 9 year prospective
study. In our study, the most frequent haplotype at the
haplotype block containing the WFS1 gene was associated
with an increased risk of diabetes. The genetic basis of
these associations is still unclear. Further studies with much
larger sample sizes are required to identify the functional
variants responsible for increased diabetes risk.
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